IL229714B - Oxazepines as ion channel modulators - Google Patents

Oxazepines as ion channel modulators

Info

Publication number
IL229714B
IL229714B IL229714A IL22971413A IL229714B IL 229714 B IL229714 B IL 229714B IL 229714 A IL229714 A IL 229714A IL 22971413 A IL22971413 A IL 22971413A IL 229714 B IL229714 B IL 229714B
Authority
IL
Israel
Prior art keywords
oxazepines
ion channel
channel modulators
modulators
ion
Prior art date
Application number
IL229714A
Other languages
English (en)
Hebrew (he)
Other versions
IL229714A0 (en
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of IL229714A0 publication Critical patent/IL229714A0/en
Publication of IL229714B publication Critical patent/IL229714B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL229714A 2011-07-01 2013-11-28 Oxazepines as ion channel modulators IL229714B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503980P 2011-07-01 2011-07-01
PCT/US2012/045021 WO2013006463A1 (en) 2011-07-01 2012-06-29 Oxazepines as ion channel modulators

Publications (2)

Publication Number Publication Date
IL229714A0 IL229714A0 (en) 2014-01-30
IL229714B true IL229714B (en) 2018-04-30

Family

ID=46513864

Family Applications (1)

Application Number Title Priority Date Filing Date
IL229714A IL229714B (en) 2011-07-01 2013-11-28 Oxazepines as ion channel modulators

Country Status (20)

Country Link
US (2) US8962610B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2966067B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP6470969B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101919634B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN107325111A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR086829A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2012279214B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112013032027A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2838234A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (2) EA025095B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2549654T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL229714B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA35808B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX338916B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO3175985T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL2966067T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT2966067T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI2726469T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI466873B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013006463A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2464645T (lt) 2009-07-27 2017-10-25 Gilead Sciences, Inc. Kondensuoti heterocikliniai junginiai, kaip jonų kanalų moduliatoriai
AU2011272787B2 (en) 2010-07-02 2015-06-18 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9115096B2 (en) 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
NO3175985T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
BR112015020716A2 (pt) * 2013-03-13 2017-07-18 Hoffmann La Roche processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e composto
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
EP3317283B1 (en) 2015-07-02 2019-04-03 H. Hoffnabb-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
WO2017042182A1 (en) 2015-09-08 2017-03-16 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
CN106046021A (zh) * 2016-05-26 2016-10-26 天津药物研究院有限公司 一类含溴的噻吩并吡啶类衍生物及其制备方法和用途
WO2018048977A1 (en) 2016-09-08 2018-03-15 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxazepin compounds
CA3045121A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
CN108084187A (zh) * 2017-12-15 2018-05-29 宜昌人福药业有限责任公司 苯并二氮杂*类氢化物
WO2019232209A1 (en) 2018-05-30 2019-12-05 Praxis Precision Medicines, Inc. Ion channel modulators
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
JP2024508789A (ja) 2021-02-19 2024-02-28 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用
CN118647617A (zh) * 2022-03-16 2024-09-13 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用

Family Cites Families (273)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2867616A (en) 1950-05-17 1959-01-06 Syntex Sa 7-dehydro diosgenin compounds and process for making same
US2867618A (en) 1957-02-14 1959-01-06 Dow Chemical Co 3, 4-dihydro-2h-1, 3-benzoxazine
US2826575A (en) 1957-05-06 1958-03-11 Dow Chemical Co 3, 3'-alkylenebis
NL128591C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1965-07-02
US3441649A (en) 1966-08-18 1969-04-29 Univ Minnesota Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
CH485411A (de) 1967-12-14 1970-02-15 Ciba Geigy Verwendung von Arylguanaminen als Antimikrobika
US3594372A (en) 1968-08-13 1971-07-20 American Home Prod Pyrimido(4,5-e)(1,4)oxazepin-5-ones and derivatives thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4062881A (en) 1974-07-26 1977-12-13 Cincinnati Milacron Chemicals, Inc. Sulfide containing tin stabilizers
US4230705A (en) 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4244953A (en) 1979-10-24 1981-01-13 American Cyanamid Company Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4812565A (en) 1982-09-30 1989-03-14 A. H. Robins Company, Incorporated Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4654343A (en) 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4746655A (en) 1987-06-10 1988-05-24 A. H. Robins Company, Incorporated Fused aromatic-spiropiperidine oxazepinones(and thiones)
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE4010488A1 (de) 1990-03-31 1991-10-02 Hoechst Ag Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten
CA2044564A1 (en) 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
CN1060467A (zh) 1990-09-25 1992-04-22 武田药品工业株式会社 1，3-苯并嗪衍生物、其生产方法和用途
JPH04209692A (ja) 1990-12-03 1992-07-31 Asahi Glass Co Ltd フォトクロミック材料
DE69219354T2 (de) 1991-05-10 1997-10-23 Takeda Chemical Industries Ltd Pyridinderivate, deren Herstellung und Anwendung
US5939412A (en) 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
WO1993000095A2 (en) 1991-06-28 1993-01-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5565449A (en) 1991-10-18 1996-10-15 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH061779A (ja) 1992-02-06 1994-01-11 Wakamoto Pharmaceut Co Ltd ベンズオキサジノン誘導体
JPH06107647A (ja) 1992-08-12 1994-04-19 Takeda Chem Ind Ltd １，３−ベンゾオキサジン誘導体の製造法
US5442055A (en) 1992-11-13 1995-08-15 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
US6011150A (en) 1992-11-13 2000-01-04 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
GB9225860D0 (en) 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
GB9226302D0 (en) 1992-12-17 1993-02-10 Smithkline Beecham Plc Pharmaceuticals
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
DE19526173A1 (de) 1995-07-18 1997-01-30 Hoechst Ag Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung
JPH09157262A (ja) 1995-12-08 1997-06-17 Tanabe Seiyaku Co Ltd アゼチジノン誘導体及びその合成中間体の製法
US5773186A (en) 1996-02-19 1998-06-30 Fuji Photo Film Co., Ltd. Heat-sensitive recording material
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
ZA976654B (en) 1996-07-26 1998-02-10 Nissan Chemical Ind Ltd Chroman derivatives.
GB9619492D0 (en) 1996-09-18 1996-10-30 Smithkline Beecham Plc Novel treatment
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
WO1998047885A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity
DE19716237A1 (de) 1997-04-18 1998-10-22 Basf Ag Substituierte Benzyloxyimino-Verbindungen
US6417362B1 (en) 1997-05-30 2002-07-09 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
JP3964053B2 (ja) 1997-07-10 2007-08-22 三井化学株式会社 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法
DE69802204T2 (de) 1997-09-08 2002-04-18 Unilever N.V., Rotterdam Verfahren zur verbesserung der enzymeaktivität
HUP0100575A3 (en) 1998-01-21 2003-03-28 Merck Sharp & Dohme Ltd Hoddes Triazolo-pyridazine derivatives as ligands for gaba receptors
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
AU2594799A (en) 1998-02-11 1999-08-30 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
JP2002517385A (ja) 1998-06-05 2002-06-18 イカゲン インク． カリウムチャネル阻害剤
CA2334836A1 (en) 1998-06-16 1999-12-23 Merck Sharp & Dohme Limited Triazolo-pyridine derivatives as ligands for gaba receptors
AU5444499A (en) 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Benzoxazine derivatives
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU6325799A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
EP1180514A4 (en) 1999-04-09 2003-02-26 Meiji Seika Kaisha NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMID DERIVATIVES, AND THEIR MEDICINAL PRODUCTS
AU4145200A (en) 1999-05-07 2000-11-21 Takeda Chemical Industries Ltd. Cyclic compounds and uses thereof
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6121916A (en) 1999-07-16 2000-09-19 Eaton-Vorad Technologies, L.L.C. Method and apparatus for recognizing stationary objects with a moving side-looking radar
WO2001016110A1 (en) 1999-08-27 2001-03-08 The Procter & Gamble Company Bleach boosting components, compositions and laundry methods
ATE311432T1 (de) 1999-08-27 2005-12-15 Procter & Gamble Stabile substanzen, zusammensetzungen und waschverfahren zu deren verwendung
CA2382119A1 (en) 1999-08-27 2001-03-08 The Procter & Gamble Company Fast-acting formulation components, compositions and laundry methods employing same
EP1206517A1 (en) 1999-08-27 2002-05-22 The Procter & Gamble Company Color safe laundry methods employing cationic formulation components
MXPA02002122A (es) 1999-08-27 2002-10-17 Procter & Gamble Disponibilidad controlada de componentes de formulacion, composiciones y metodos de lavanderia que emplean los mismos..
WO2001016276A1 (en) 1999-08-27 2001-03-08 The Procter & Gamble Company Stability enhancing formulation components, compositions and laundry methods employing same
WO2001016278A1 (en) 1999-08-27 2001-03-08 The Procter & Gamble Company Color safe laundry methods employing zwitterionic formulation components
EP1212314B1 (en) 1999-09-17 2005-11-30 Nissan Chemical Industries, Ltd. Benzopyran derivative
AU7319800A (en) 1999-09-24 2001-04-24 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
AU7453900A (en) 1999-10-05 2001-05-10 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2393756A1 (en) 1999-12-21 2001-06-28 Aimee D. Reed Potassium channel inhibitors
US6469020B2 (en) 2000-05-15 2002-10-22 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives
HUP0303070A2 (hu) 2000-08-01 2003-12-29 Ono Pharmaceutical Co., Ltd. 3,4-Dihidro-izokinolin-származékok és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
AU2001288485A1 (en) 2000-08-29 2002-03-13 Balekudru Devadas Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
ATE384701T1 (de) 2000-09-20 2008-02-15 Merck & Co Inc Isochinolinone als kalium-kanal-inhibitoren
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002051441A1 (fr) 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
KR20030080087A (ko) 2001-03-09 2003-10-10 화이자 프로덕츠 인코포레이티드 항염증제로서의 트리아졸로피리딘
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
HUP0400362A3 (en) 2001-06-25 2007-05-29 Nissan Chemical Ind Ltd Substituted benzopyran derivetives against arrhythmia
JP2005089298A (ja) 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
TW200300347A (en) 2001-11-13 2003-06-01 Schering Corp Nk1 antagonists
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
JP2003277384A (ja) 2002-03-26 2003-10-02 Kyorin Pharmaceut Co Ltd 縮合ニ環式ピリジン誘導体
JP2003321461A (ja) 2002-04-25 2003-11-11 Kyorin Pharmaceut Co Ltd 縮合ビフェニル誘導体
JP2005539020A (ja) 2002-08-13 2005-12-22 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としてのクロモン誘導体
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
US20040242572A1 (en) 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
WO2004026292A1 (ja) 2002-09-20 2004-04-01 Tsumura & Co. 鎮咳薬
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
AU2003294235A1 (en) 2002-10-22 2004-05-13 The Trustees Of The University Of Pennsylvania Fragments and activity of rel protein in m. tuberculosis adn other uses thereof
CN100430386C (zh) 2002-11-07 2008-11-05 默克公司 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病
JP4413863B2 (ja) 2002-11-07 2010-02-10 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
WO2004062616A2 (en) 2003-01-13 2004-07-29 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE10317526A1 (de) 2003-04-16 2004-11-04 Degussa Ag Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen
CN100384856C (zh) 2003-04-17 2008-04-30 麦克公司 趋化因子受体活性调节剂杂环基环戊基四氢异喹啉和杂环基环戊基四氢吡啶并吡啶
WO2004096767A1 (en) 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
WO2004101509A2 (en) 2003-05-06 2004-11-25 Case Western Reserve University Functionalized benzoxazines, polymers and copolymers thereof
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1641803B3 (en) 2003-06-11 2010-12-08 Xention Limited Thienopyrimidine derivatives as potassium channel inhibitors
US20060148805A1 (en) 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
BRPI0412247A (pt) 2003-07-21 2006-09-19 Solvay Pharm Gmbh uso de compostos 3,7-diazabiciclo[3.3.1]nonano para o tratamento e/ou profilaxia de episódios arrìtmicos em doentes humanos do sexo masculino
AU2004263515A1 (en) 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels
DE10348298A1 (de) 2003-10-17 2005-05-19 Solvay Pharmaceuticals Gmbh Amidomethyl-substituierte 2-(4-Sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-ylderivade, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
TW200514582A (en) 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
KR20060120205A (ko) 2003-12-18 2006-11-24 화이자 프로덕츠 인코포레이티드 ｐ38 ＭＡＰ 키나제 억제제를 사용하여 동물의 급성 염증을치료하는 방법
EP1731512B9 (en) 2004-03-05 2017-03-01 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and noxious organism control agent
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JP4955557B2 (ja) 2004-06-10 2012-06-20 ゼンション・リミテッド カリウムチャネル阻害剤として有効なフラノピリミジン化合物
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
WO2006002470A1 (en) 2004-06-30 2006-01-12 Monash University Chiral ligands for asymmetric catalysis
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
US7572783B2 (en) 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
DE602005022320D1 (de) 2004-08-23 2010-08-26 Merck Sharp & Dohme Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
ATE518852T1 (de) 2004-09-13 2011-08-15 Merck Sharp & Dohme Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US20060094003A1 (en) 2004-11-01 2006-05-04 Stanley Nattel Acetylcholine-dependent current as a novel ionic target for atrial fibrillation
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
JP2006203875A (ja) 2004-12-24 2006-08-03 Matsushita Electric Ind Co Ltd 受信装置
WO2006091897A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
KR100609101B1 (ko) 2005-03-11 2006-08-08 주식회사 신화성물산 물수건 공급장치의 물 분사노즐 및 그 제조방법
US7714150B2 (en) 2005-04-12 2010-05-11 Solvay Pharmaceuticals Gmbh Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives
DE602006016420D1 (de) 2005-04-12 2010-10-07 Abbott Products Gmbh Aminoalkylamidomethylsubstituierte 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-cromen-6-yl derivate und ihre verwendung als kaliumkanalblocker
WO2006113432A2 (en) 2005-04-14 2006-10-26 Smithkline Beecham Corporation Compounds, compositions and methods
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
PL1881823T3 (pl) 2005-05-17 2015-05-29 Sarcode Bioscience Inc Kompozycje i sposoby leczenia chorób oczu
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
JP2008543867A (ja) 2005-06-17 2008-12-04 ワイス セロトニン阻害剤ならびに５−ｈｔ１ａアゴニストおよびアンタゴニストとして有用な三環系化合物
WO2007004028A2 (en) 2005-06-30 2007-01-11 Ranbaxy Laboratories Limited Processes for the preparation of penems and its intermediate
WO2007004960A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer’s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson’s disease
GB0516963D0 (en) 2005-08-18 2005-09-28 Carbonite Corp Liquid dispensers
EP1932549B1 (en) 2005-08-26 2016-12-28 AMNOS Co., Ltd. Dried amnion and method for drying treatment of amnion
WO2007038138A2 (en) 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
US7482360B2 (en) 2005-09-23 2009-01-27 Schering Corporation Fused tetracyclic mGluR1 antagonists as therapeutic agents
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
US7851464B2 (en) 2005-11-18 2010-12-14 Merck Sharp & Dohme Corp. Spirolactam aryl CGRP receptor antagonists
JP2009515976A (ja) 2005-11-18 2009-04-16 メルク エンド カムパニー インコーポレーテッド スピロラクタム二環式ｃｇｒｐ受容体アンタゴニスト
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
KR20080082618A (ko) 2005-12-16 2008-09-11 알콘, 인코퍼레이티드 Ａｌｋ5 조절제를 사용한 안압의 조절
US8013073B2 (en) 2005-12-30 2011-09-06 Chevron Oronite Company Llc Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
JP2009531390A (ja) 2006-03-31 2009-09-03 ノバルティス アクチエンゲゼルシャフト 有機化合物
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
CN101500575A (zh) 2006-06-12 2009-08-05 沃泰克斯药物股份有限公司 可用作离子通道调控剂的噻吩并嘧啶
WO2008005338A1 (en) 2006-06-29 2008-01-10 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
JP5642963B2 (ja) 2006-06-30 2014-12-17 スネシス ファーマシューティカルズ，インコーポレイティド ピリジノニルｐｄｋ１阻害剤
US20090318412A1 (en) 2006-07-11 2009-12-24 Takahiro Matsumoto Tricyclic heterocyclic compound and use thereof
AU2007272009A1 (en) 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
MX2009001963A (es) 2006-08-22 2009-03-30 Ranbaxy Lab Ltd Inhibidores de metaloproteinasa de matriz.
MX2009003650A (es) 2006-10-06 2009-04-22 Abbott Lab Nuevos imidazotiazoles e imidazoxazoles.
MX2009003874A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
ES2532899T3 (es) 2006-10-28 2015-04-01 Methylgene Inc. Derivados de dibenzo[b,f][1,4]oxazepina como inhibidores de histona desacetilasa
WO2008053913A1 (fr) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
EP2101775A1 (en) 2006-12-21 2009-09-23 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
JP2010520237A (ja) 2007-02-28 2010-06-10 メルク・シャープ・エンド・ドーム・コーポレイション ナトリウムチャネル遮断薬としての置換ベンゾジアゼピノン、ベンゾオキサアゼピノン及びベンゾチアゼピノン
US8247403B2 (en) 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
MX2009010895A (es) 2007-04-12 2009-10-26 Cv Therapeutics Inc Ranolazina para aumentar la secrecion de insulina.
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
WO2008144483A2 (en) 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
WO2009026444A1 (en) 2007-08-22 2009-02-26 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
CA2699384A1 (en) 2007-09-12 2009-03-19 Wyeth Llc Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2011507883A (ja) 2007-12-19 2011-03-10 ワイス・エルエルシー Ｋｖ１．５カリウムチャネル阻害剤としての４−イミダゾリジノン
CA2709187A1 (en) 2007-12-19 2009-06-25 Wyeth Llc 4-imidazolidinones as kv1.5 potassium channel inhibitors
WO2009085980A1 (en) 2007-12-19 2009-07-09 Genentech, Inc. 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
WO2009089027A1 (en) 2008-01-09 2009-07-16 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health Phosphodiesterase inhibitors
EA201070914A1 (ru) 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
EP2241567A4 (en) 2008-02-13 2011-11-09 Eisai R&D Man Co Ltd Bicycloamine DERIVATIVE
JP2009286773A (ja) 2008-03-14 2009-12-10 Bayer Cropscience Ag 殺虫性縮環式アリール類
WO2009137462A2 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Methods for treating cognitive disorders using inhibitors of histone deacetylase
WO2009137499A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Inhibitors of histone deacetylase
DE102008024182A1 (de) 2008-05-19 2009-11-26 Merck Patent Gmbh Verbindungen für organische elektronische Vorrichtung
WO2009148452A1 (en) 2008-06-06 2009-12-10 Abbott Laboratories Novel 1,2,4 oxadiazole compounds and methods of use thereof
CA2726508C (en) 2008-06-17 2016-06-07 Astrazeneca Ab Pyridine compounds
EP2307027A4 (en) 2008-07-11 2012-08-15 Neumedics TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE PROPERTIES
MY147281A (en) 2008-07-31 2012-11-30 Invenpro M Sdn Bhd An apparatus for washing a workpiece
AU2009277232B2 (en) 2008-07-31 2012-03-29 Poh Huay Chua Pet carrier
WO2010018686A1 (ja) 2008-08-12 2010-02-18 日本曹達株式会社 含窒素ヘテロ環誘導体および農園芸用殺菌剤
CA2734449A1 (en) 2008-08-18 2010-02-25 Ube Industries, Ltd. Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CA2735653A1 (en) 2008-09-04 2010-03-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
US20100113461A1 (en) 2008-10-29 2010-05-06 Gilead Palo Alto, Inc. Substituted heterocyclic compounds
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
US8389500B2 (en) 2008-10-30 2013-03-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010056865A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
WO2010068461A1 (en) 2008-11-25 2010-06-17 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
WO2010063634A1 (en) 2008-12-05 2010-06-10 F. Hoffmann-La Roche Ag Pyrrolopyrazinyl urea kinase inhibitors
MX2011006108A (es) 2008-12-08 2011-11-18 Vm Pharma Llc Composiciones de inhibidores de los receptores tirosina quinasa.
SG172001A1 (en) 2008-12-08 2011-07-28 Sirtris Pharmaceuticals Inc Isoindolinone and related analogs as sirtuin modulators
JP5271069B2 (ja) 2008-12-24 2013-08-21 三和シヤッター工業株式会社 開閉装置
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 ｃ형 간염 억제제
US20100305093A1 (en) * 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
LT2464645T (lt) 2009-07-27 2017-10-25 Gilead Sciences, Inc. Kondensuoti heterocikliniai junginiai, kaip jonų kanalų moduliatoriai
BR112012006807A2 (pt) * 2009-09-28 2020-11-03 F.Hoffmann-La Roche Ag compostos da fórmula i, composição farmacêutica, composta por composto, método de tratamento de câncer em um mamífero, uso de um composto, kit para tratar um condição mediada por pi3k e processo para a preparação de um composto
US20120264636A1 (en) 2009-10-07 2012-10-18 Decode Genetics Ehf. Genetic variants indicative of vascular conditions
WO2011056985A2 (en) * 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
CN102791687B (zh) 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US8323911B2 (en) 2010-05-13 2012-12-04 University Of South Carolina High throughput assay for discovering new inhibitors of the GIRK1/4 channel
AU2011272787B2 (en) 2010-07-02 2015-06-18 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012019071A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating sarcopenia
WO2012019076A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
WO2012037105A1 (en) 2010-09-14 2012-03-22 The Trustees Of Columbia University In The City Of New York Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases
WO2012036233A1 (ja) 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
HUE027195T2 (en) 2010-09-21 2016-10-28 Purdue Pharma Lp Buprenorphine analogs as opioid receptor agonists and/or antagonists
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
EP2643316A2 (en) 2010-11-24 2013-10-02 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
WO2012074469A1 (en) 2010-11-30 2012-06-07 Astrazeneca Ab New ikach blockers
JP5675428B2 (ja) 2011-02-25 2015-02-25 サンドビック株式会社 ベルトプレス装置
KR20140032383A (ko) * 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법
US9115096B2 (en) 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CA2836904C (en) 2011-06-03 2019-09-24 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2011-07-01 2018-04-28
WO2013004551A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
US20140221286A1 (en) 2011-09-21 2014-08-07 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
EP2861254B1 (en) 2012-06-13 2020-04-29 Acesion Pharma ApS Pharmaceutical compositions for combination therapy
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
TW201613908A (en) 2014-02-13 2016-04-16 Gilead Sciences Inc Solid forms of an ion channel modulator
CN104844535A (zh) 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法

Also Published As

Publication number Publication date
PL2726469T3 (pl) 2016-01-29
US8962610B2 (en) 2015-02-24
NO3175985T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-04-28
JP2018203771A (ja) 2018-12-27
EA025095B1 (ru) 2016-11-30
PL2966067T3 (pl) 2018-04-30
US20130005706A1 (en) 2013-01-03
CN103635467B (zh) 2017-08-04
WO2013006463A1 (en) 2013-01-10
HK1219098A1 (en) 2017-03-24
KR101919634B1 (ko) 2018-11-16
TW201313692A (zh) 2013-04-01
EA031189B1 (ru) 2018-11-30
ES2549654T3 (es) 2015-10-30
JP6470969B2 (ja) 2019-02-13
KR20140045394A (ko) 2014-04-16
AU2012279214B2 (en) 2015-07-30
ES2657169T3 (es) 2018-03-01
EA201690899A1 (ru) 2016-12-30
EP2966067A1 (en) 2016-01-13
BR112013032027A2 (pt) 2016-09-06
MA35808B1 (fr) 2014-12-01
TWI466873B (zh) 2015-01-01
MX338916B (es) 2016-05-03
MX2013014843A (es) 2014-03-31
CN103635467A (zh) 2014-03-12
US20150239904A1 (en) 2015-08-27
AR086829A1 (es) 2014-01-22
EA201391628A1 (ru) 2014-06-30
SI2726469T1 (sl) 2015-10-30
JP2017088630A (ja) 2017-05-25
US9695192B2 (en) 2017-07-04
PT2726469E (pt) 2015-10-27
EP2966067B1 (en) 2017-10-25
AU2012279214A1 (en) 2013-05-02
CN107325111A (zh) 2017-11-07
IL229714A0 (en) 2014-01-30
EP2726469A1 (en) 2014-05-07
JP2014518277A (ja) 2014-07-28
EP2726469B1 (en) 2015-08-12
HK1197061A1 (en) 2015-01-02
PT2966067T (pt) 2018-01-30
NZ618684A (en) 2016-02-26
SI2966067T1 (en) 2018-02-28
CA2838234A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
IL256779A (en) Benzoxazepines are fused ion channel modulators
IL229714A0 (en) Oxazepines as ion channel modulators
GB2505607B (en) Channel division
GB2491139B (en) Channel access control
GB2506362B (en) Improved ion guide
EP3008748A4 (en) Ion optical elements
GB201220942D0 (en) Finfet
ZA201403050B (en) R(+)-n-methyl-propargyl-aminoindan
GB2549036B (en) RF ion guides
ZA201403043B (en) R(+)-n-formyl-propargyl-aminoindan
GB2497382B (en) Annular ion guide
GB2492051B (en) Channel bandwidth
ZA201400681B (en) Off-gas channel
EP2676305A4 (en) ELECTROACTIVE COMPOSITION
IL213611A0 (en) Secure fast channel changing
HK1197061B (en) Oxazepines as ion channel modulators
GB201111471D0 (en) Improved ion source
AU2012900602A0 (en) Ion channel inhibitors
ZA201404922B (en) Retaining walls
AU2011901859A0 (en) Scramble
GB201217184D0 (en) Improved ion guide
GB201113595D0 (en) Switching means
GB201116059D0 (en) Project P
GB201104189D0 (en) Ionisation device-II

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed